Can New Chapter Calcium Supplement Help with Cancer?

Overview

SCIENTIFIC SCORE

Possibly Effective

Based on 22 Researches

7.6

USERS' SCORE

Good

Based on 2 Reviews

8.5

Top Medical Research Studies

Vitamin D3 offers anti-cancer benefits

Ezcurra-Hualde M, Zalba S, Bella Á, Arrizabalaga L, Risson A, et al. Liposomal encapsulation of cholecalciferol mitigates toxicity and delays tumor growth. Front Immunol. 2025;16:1529007. doi:10.3389/fimmu.2025.1529007

We investigated the potential of vitamin D3, also known as cholecalciferol, in combating cancer while addressing concerns about its toxicity at higher doses. This study focused on enhancing the effectiveness of vitamin D3 through a clever method called liposomal encapsulation, which helps minimize side effects.

We prepared liposomal vitamin D3 (VD-LP) and conducted various tests to understand its capabilities. We found that this encapsulated form not only maintained high efficiency but also demonstrated improved stability. Our analyses showed that VD-LP had strong effects against cancer cells from colorectal, breast, and prostate cancers. Remarkably, it affected gene expression in immune cells, boosting elements that help fight infections and support the body's defenses.

Notably, VD-LP did a great job slowing tumor growth in mice and improved their survival rates without causing adverse effects like hypercalcemia, which is often a concern with regular vitamin D3 use. This evidence indicates that liposomal encapsulation of vitamin D3 could offer an effective cancer treatment strategy while minimizing unwanted side effects.

We believe this may pave the way for further research and clinical applications, showcasing vitamin D3 as a valuable addition to cancer therapy.

Vitamin D3 derivatives improve cancer treatment

Kittaka A. Synthetic Studies on Vitamin D Derivatives with Diverse but Selective Biological Activities. Chem Pharm Bull (Tokyo). 2025;73:1. doi:10.1248/cpb.c24-00598

We focused on how modified forms of vitamin D3 can positively affect cancer treatment. The study revealed that a specific derivative, known as MART-10, demonstrated significant anti-tumor effects in mouse models. When administered at low doses, this compound showed robust anti-cancer activity against BxpC-3 cancer cells.

Additionally, we explored a new vitamin D analog, AH-1, which was found to enhance bone formation without the usual side effects associated with vitamin D treatments. This is particularly promising for osteoporosis patients. Another derivative named NS-74c even exhibited potent antagonist activity against the vitamin D receptor, indicating a potential for varied therapeutic uses.

Overall, our research highlighted the potential of vitamin D3 derivatives to tackle cancer while minimizing adverse effects. This approach opens new doors for therapeutic options in oncology, providing a glimpse into how modified vitamin D can improve treatment outcomes for patients.

Vitamin D's potential in CRC

Wang L, Xu R, Wang M, Wang M, Su S, et al. Exploration and Identification of Vitamin D and Related Genes as Potential Biomarkers for Colorectal Tumors. Onco Targets Ther. 2025;18:129. doi:10.2147/OTT.S495066

We delved into the intriguing relationship between vitamin D and colorectal cancer (CRC) to uncover how this nutrient might influence cancer development and treatment. The study involved measuring the serum levels of active vitamin D (1,25(OH)D) in different groups, including those with normal conditions, colorectal adenomas (CRA), and colorectal cancer (CRC).

Our findings highlighted a significant drop in vitamin D levels in CRC patients, with levels falling to 19.00 µg/mL compared to 42.99 µg/mL in normal individuals. Additionally, we conducted bioinformatics analysis to pinpoint genes linked to vitamin D and colorectal cancer, testing these using HCT116 and HT29 cell lines.

We observed that vitamin D can inhibit the growth and spread of colon cancer cells, leading to a reduction in the activity of certain cancer-promoting genes. Interestingly, our analysis also showed that a diagnostic model based on five key vitamin D-related genes exhibited high diagnostic efficiency. This reveals vitamin D's potential as a supportive approach for CRC diagnosis and treatment, offering hope for improved cancer management.

Most Useful Reviews

Best calcium sourced

10 people found this helpful

This is the only calcium I will take. Having thyroid cancer requires me to consume a significant amount of calcium daily. My blood work confirms that this brand is the most effective. Previous drugstore brands left me with low calcium levels, but with New Chapter, I take less while ensuring better absorption.

7.5

Stable bone health

6 people found this helpful

My endocrinologist has indicated that I am managing my health well. I transitioned from osteopenia to osteoporosis while fighting cancer – and winning! There has been no advancement of osteoporosis, which is a relief. My routine includes two tablets in the morning and obtaining the rest of my calcium from diet, alongside additional vitamin D.

Medical Researches

SCIENTIFIC SCORE

Possibly Effective

Based on 22 Researches

7.6

Vitamin D enhances chemotherapy delivery

Peixoto D, Ravasco JM, Blanco-Fernandez B, Veiga F, Concheiro A, et al. Enzyme-responsive vitamin D-based micelles for paclitaxel-controlled delivery and synergistic pancreatic cancer therapy. Mater Today Bio. 2025;31:101555. doi:10.1016/j.mtbio.2025.101555

We explored the potential of vitamin D-based micelles designed to deliver paclitaxel, a key chemotherapy drug, specifically for pancreatic cancer treatment. This study focuses on developing enzyme-responsive micelles that not only carry paclitaxel but also utilize vitamin D as an integral part of the delivery system.

The micelles are made by combining vitamin D with polyethylene glycol, resulting in tiny structures that can release their drug load when interacting with enzymes typically found in pancreatic cancer cells. We observed that these micelles showed promising results in laboratory settings, enhancing the effectiveness of paclitaxel against aggressive pancreatic cancer cells compared to using paclitaxel alone.

Moreover, we noted that the vitamin D in the micelles may play a dual role: serving as both a hydrophobic core for drug delivery and a contributor to synergetic therapeutic effects. Our findings suggest that leveraging vitamin D in this way could increase the efficacy of existing treatment options for pancreatic cancer patients, which is particularly significant given the challenges currently faced in treating this disease.

Vitamin D3 derivatives improve cancer treatment

Kittaka A. Synthetic Studies on Vitamin D Derivatives with Diverse but Selective Biological Activities. Chem Pharm Bull (Tokyo). 2025;73:1. doi:10.1248/cpb.c24-00598

Magnesium and Cancer Treatment Outcomes

Wang Z, Wang Z. Letter Re: Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers. Eur J Cancer. 2025;216:115187. doi:10.1016/j.ejca.2024.115187

We looked into the question of how magnesium levels might affect cancer treatment outcomes, especially for patients receiving immune checkpoint blockers. The study pointed out that elevated serum magnesium levels corresponded with more favorable results in these patients, suggesting that magnesium could play a positive role in their treatment journey.

However, the findings did not specifically isolate the effects of magnesium from those of other treatments. This means that while we observed a correlation between high magnesium levels and improved outcomes, we can't definitively say that magnesium alone caused these results. It’s important to note that further research is needed to clarify this relationship and understand how magnesium interacts with cancer therapies.

Overall, while the presence of sufficient magnesium appears to be beneficial, the intricate connection between magnesium levels and cancer treatment success is still not fully understood.

Magnesium enhances cancer immunotherapy

Hao H, Sun S, Fu Y, Wen S, Wen Y, et al. Magnesium peroxide-based biomimetic nanoigniter degrades extracellular matrix to awake T cell-mediated cancer immunotherapy. Biomaterials. 2025;317:123043. doi:10.1016/j.biomaterials.2024.123043

We examined how magnesium plays a role in enhancing T cell-mediated cancer immunotherapy. The study focused on a unique magnesium peroxide-based nanoigniter designed to disrupt the tumors' defenses. By combating the challenging immunosuppressive environment surrounding tumors, this innovative treatment aims to allow T cells to attack more effectively.

The nanoigniter is loaded with doxorubicin and metformin, and it works doubly by breaking down the tough extracellular matrix (ECM) that makes it difficult for T cells to infiltrate tumors. We observed that this approach not only promotes stronger responses from CD8 T cells — a critical type of immune cell in our bodies — but also boosts their effectiveness and prevents their fatigue under harsh conditions.

While the study highlights magnesium's supportive role in improving immunotherapy outcomes, it does not isolate the mineral's direct impact on cancer. Therefore, while we see promising interactions, determining magnesium's specific effects remains complex and linked to the overall treatment plan.

Magnesium enhances glioblastoma treatment

Li W, Tian H, Yan Z, Yu X, Li B, et al. Magnesium-Phenolic Nanoeditor Refining Gliomatous T Cells for Metalloimmunotherapy. ACS Nano. 2025;19:1222. doi:10.1021/acsnano.4c13388

We investigated how magnesium might enhance the effectiveness of cytotoxic T lymphocytes (CTLs) in fighting glioblastoma, a particularly aggressive form of brain cancer. CTLs, although present in glioblastoma, often struggle to infiltrate tumors effectively and are hampered by various inhibitory markers, notably NK1.1.

This study introduced a novel method using a specially designed nanoeditor, named Mg@MK-8931@MPP. This editor combines magnesium with a specific drug that helps empower CTLs and encourages their infiltration into the tumor while addressing the challenges of delivering treatment safely in the brain.

We observed that once the magnesium-based nanoeditor localized within glioblastoma, it enabled the effective release of MK-8931. This release repolarized M2-like macrophages, promoting a more significant CTL presence within the tumor site. Furthermore, magnesium worked to amplify the immune response, boosting the production of crucial antitumor cytokines and proteins.

Additionally, we found that blocking the NK1.1 receptor on CTLs extended their cytotoxic activity, enhancing treatment outcomes. Research on both T-cell-deficient and standard mouse models validated the potential of this magnesium-driven metalloimmunotherapy approach in treating glioblastoma effectively.

Overall, this strategy not only broadens the application of metalloimmunotherapy to glioblastoma but also emphasizes the importance of ensuring the functionality of CTLs in the fight against cancer.

Load More Researches

User Reviews